A practical learning platform for pharmaceutical safety teams. Learn how signal management works from detection and validation to assessment, regulatory action and closure — then practise the reasoning with a guided case-flow tool.
Signal management is not simply counting adverse-event reports. It is the systematic process of identifying and evaluating information that may indicate a new potentially causal association, or a new aspect of a known association, and deciding whether further investigation or action is warranted.
Signals can reveal new risks, changes in known risks, affected populations, interactions, patterns of use or other safety information that may matter to patients and regulators.
Safety signals may emerge from spontaneous reports, EudraVigilance, clinical studies, literature, epidemiology, registries, product data, regulatory information and other appropriate sources.
Signal processes evolve with legislation, data availability, methods, terminology, product knowledge and regulatory decisions. Role-based training supports consistent and defensible safety reasoning.
The learning model uses nine linked stages. In real organisations the exact terminology, ownership and governance may vary, but the scientific logic should remain traceable from first observation to final action and monitoring.
Article 18 of Implementing Regulation (EU) No 520/2012, as amended, requires MAHs to monitor EudraVigilance data and use it together with data from other available sources. The former Article 21(2) MAH provision was deleted. For EudraVigilance monitoring, Article 19 now specifies that signals related to a suspected adverse reaction are considered. Open the amending Regulation ↗
Work through a hypothetical safety pattern using predefined choices. The result is an educational reasoning path, not a regulatory classification, not a validated signal decision and not a substitute for a Safety Scientist, medical review, QPPV oversight, company SOPs or competent-authority assessment.
Do not enter patient, reporter or company-confidential information. Use only the predefined learning choices.
Move through the four steps. The coach will show which signal-management questions deserve attention and how the case would typically move through a structured learning workflow.
Each module combines concise theory, practical reasoning, role relevance and an official reference. The curriculum moves from fundamental signal concepts to advanced benefit-risk, governance and regulatory action.
Signal-management competence should match the decisions a person makes. A case processor needs recognition and escalation; a safety scientist needs deeper evidence synthesis; QPPV and governance roles need oversight, regulatory context and benefit-risk decision awareness.
Titles differ between companies, but signal management is usually multidisciplinary and connects case processing, medicine, epidemiology, data science, aggregate reporting, regulatory affairs and governance.
Short prompts for training sessions, case discussions and self-study. They are memory aids only and should never replace approved procedures, validated tools or documented medical assessment.
The EU signal-management framework is changing. Use the current legislation, current EMA Q&A and current GVP alongside your organisation's controlled procedures. Do not assume an older training deck still reflects the 2026 legal position.
Choose a level and answer scenario-based questions. Explanations focus on why an answer is safer or more scientifically defensible, rather than memorising terminology.
Select a level and start when ready.
Key terms used throughout safety surveillance and signal governance.